First-line Therapy: Time-Limited Venetoclax Doublet Therapy.

IF 2.7 3区医学 Q2 HEMATOLOGY

Hematology-Oncology Clinics of North America Pub Date : 2025-07-11 DOI:10.1016/j.hoc.2025.05.007

Jennifer Huang, Mazyar Shadman

引用次数: 0

Abstract

Studies examining venetoclax in combination with anti-CD20 monoclonal antibodies and covalent Bruton tyrosine kinase inhibitors (BTKi) demonstrated a progression-free survival and in some cases overall survival benefit over chemoimmunotherapy. It is currently unclear what is the most optimal combination partner for a B-cell leukemia/lymphoma 2 inhibitor (BCL2i). We are eagerly awaiting results from studies to determine the most effective BCL2i and BTKi combination for the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma given the development of second-generation drugs.

查看原文本刊更多论文

一线治疗：有时间限制的Venetoclax双重治疗。

对venetoclax联合抗cd20单克隆抗体和共价布鲁顿酪氨酸激酶抑制剂（BTKi）的研究表明，与化学免疫疗法相比，在某些情况下，venetoclax的无进展生存期和总生存期都有所改善。目前尚不清楚b细胞白血病/淋巴瘤2抑制剂（BCL2i）的最佳联合伙伴是什么。鉴于第二代药物的发展，我们急切地等待研究结果，以确定BCL2i和BTKi联合治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的最有效的一线治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology-Oncology Clinics of North America 医学-血液学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.